Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rapport Therapeutics
Biotech
FDA places Rapport's nerve damage trial on hold
The FDA has placed a trial of Rapport Therapeutics’ epilepsy drug for a type of nerve pain on hold while the biotech tweaks the study design.
James Waldron
Nov 7, 2024 8:50am
Rapport upsizes IPO, tacking on $32M
Jun 7, 2024 11:00am
Rapport talks up $122M IPO for proof-of-concept epilepsy trials
Jun 3, 2024 7:10am
Third Rock, J&J neuroscience spinout Rapport outlines IPO plans
May 20, 2024 5:13am
MHRA CEO Raine to depart in Autumn —Chutes & Ladders
Mar 1, 2024 9:30am
Illumina nets new CEO—Chutes & Ladders
Sep 8, 2023 9:30am
